STING 激动剂与抗血管 RGD-(KLAKLAK)(2) 肽联合作为一种新型抗肿瘤疗法

Immunotherapy is one of the most promising anti-cancer treatment. It involves activating the host's own immune system to eliminate cancer cells. Activation of cGAS-STING pathway is promising therapeutic approach for cancer immunotherapy.

However, in human clinical trials, targeting cGAS-STING pathway results in insufficient or unsustainable anti-tumor response. To enhance its effectiveness, combination with other anti-cancer therapies seems essential to achieve synergistic systemic anti-tumor response. The aim of this study was to evaluate whether the combination of STING agonist-cGAMP with anti-vascular RGD-(KLAKLAK) 2 peptide results in a better anti-tumor response in poorly immunogenic tumors with various STING protein and α v β 3 integrin status.

Combination therapy inhibited growth of murine breast carcinoma more effectively than melanoma. In melanoma, the administration of STING agonist alone was sufficient to obtain a satisfactory therapeutic effect. In both tumor models we have noted stimulation of innate immune response following cGAMP administration alone or in combination. The largest population of immune cells infiltrating the TME after therapy were activated NK cells. Increased infiltration of cytotoxic CD8 + T lymphocytes within the TME was only observed in melanoma tumors.

However, they also expressed the "exhaustion" PD-1 receptor. In contrast, in breast carcinoma tumors each therapy caused the drop in the number of infiltrating CD8 + T cells. The obtained results indicate an additional therapeutic benefit from combining STING agonist with an anti-vascular agent.

However, this effect depends on the type of tumor, the status of its microenvironment and the expression of specific proteins such as STING and α v β 3 family integrin.